Lymfom kliniske forsøg i Ohio
29 studier for Lymfom søger deltagere på steder i Ohio.
Byer i Ohio
Officiel studietekst (engelsk)
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
- University Hospitals Seidman Cancer Center, Cleveland
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT06343311Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Cincinnati Children's Hospital Medical Center, Cincinnati
RekruttererObservationsstudie
Alder 0 til 38 · Alle køn · Opdateret 1. okt. 2026 · NCT06131801A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- University Hospitals Cleveland Medical Center, Cleveland
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT07192471A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
- Cleveland Clinic, Cleveland
- The Ohio State University Comprehensive Cancer Center, Columbus
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT07015242A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
- University Hospitals Cleveland Medical Center, Cleveland
RekruttererFase 2
1 Month – 17 Years · Alle køn · Opdateret 30. sep. 2026 · NCT04570423Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
- Cincinnati Children's Hospital Medical Center, Cincinnati
RekruttererFase 1
24 Months – 18 Years · Alle køn · Opdateret 25. sep. 2026 · NCT06441331Epco, Zanu, Ritux for R/R FL or MZL
- The Ohio State University Wexner Medical Center, Columbus
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06563596Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
- Ohio State University Comprehensive Cancer Center, Columbus
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT04301076A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- University of Cincinnati, Cincinnati
- The Cleveland Clinic Foundation, Cleveland
- The Ohio State University, Columbus
- og 1 flere
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 17. sep. 2026 · NCT07221500Collection of Tissue Samples for Cancer Research
- Ohio State University, Columbus
RekruttererObservationsstudie
2 Months · Alle køn · Opdateret 16. sep. 2026 · NCT00900198CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- Cincinnati Children's Hospital Medical Center, Cincinnati
RekruttererFase 1/2
12 Months – 21 Years · Alle køn · Opdateret 11. sep. 2026 · NCT04870944Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Cleveland
RekruttererFase 3
Alder 18 til 18 · Alle køn · Opdateret 8. sep. 2026 · NCT07509151Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- University of Cincinnati (UC) Physicians Company, LLC, Cincinnati
- Cleveland Clinic, Cleveland
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 25. aug. 2026 · NCT05826535A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
- Cleveland Clinic, Cleveland
RekruttererFase 1/2
Alder 12 og opefter · Alle køn · Opdateret 20. aug. 2026 · NCT06678659A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
- University of Cincinnatti Medical Center, Cincinnatti
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 17. aug. 2026 · NCT06528301Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- The Ohio State University Wexner Medical Center, Columbus
RekruttererFase 1/2
Alder 13 til 90 · Alle køn · Opdateret 6. aug. 2026 · NCT06533579A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Oncology Hematology Care Clinical Trials, Cincinnati
- University of Cincinnati, Cincinnati
- Cleveland Clinical Taussig Cancer Center, Cleveland
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 4. aug. 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- The Ohio State University Wexner Medical Center James Cancer, Columbus
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 13. jul. 2026 · NCT04792489A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
- University Hospitals Cleveland Medical Center, Cleveland
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 8. jul. 2026 · NCT07465835A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- University of Cincinnati Medical Center, Cincinnati
- Cleveland Clinic, Cleveland
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. jul. 2026 · NCT05131022A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
- Dren Investigational Site, Columbus
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 17. jun. 2026 · NCT05475925Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 18. maj 2026 · NCT01790152Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies
- The Ohio State University, Columbus
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 24. apr. 2026 · NCT06801002CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Cleveland Clinic, Cleveland
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 16. apr. 2026 · NCT03328078Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
- Ohio State University Comprehensive Cancer Center, Columbus
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 15. apr. 2026 · NCT07356245The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Gabrail Cancer Center Research,, Canton
RekruttererFase 1/2
Alder 12 til 95 · Alle køn · Opdateret 15. apr. 2026 · NCT04329728cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Cleveland Clinic, Cleveland
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 40 og opefter · Alle køn · Opdateret 20. jan. 2026 · NCT05366881Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 10. nov. 2025 · NCT06916767HPC Offered for PRESERVE Expansion
- The Ohio State University Medical Center, Columbus
RekruttererObservationsstudie
Alder 12 til 80 · Alle køn · Opdateret 28. aug. 2025 · NCT07145411Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.